Yahoo Finance

Celgene (CELG) and Acceleron Pharma (XLRN) announced interim data from two studies of candidates from the companies’ joint development program in beta-thalassemia. The data presented at the 19th European Hematology Association, EHA, annual congress show activity for two programs, sotatercept and ACE-536, in patients with both transfusion dependent and non-transfusion dependent beta-thalassemia. There is currently no drug approved to treat beta-thalassemia. Both sotatercept and ACE-536 have been granted orphan drug designation for beta-thalassemia by the FDA.